Adagrasib (CAS: 2326521-71-3) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. Adagrasib covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction.
|
Technical Data
|
|
Appearance:
|
Off White Solid
|
|
Purity:
|
> 98%
|
|
QC Data:
|
 View Current Lot Data File
|
|
CAS:
|
2326521-71-3
|
|
Storage
|
-20°C, long term; 4°C, short term
|
|
Shipping
|
Room temperature
|
TGF-beta/Smad
Bombesin Receptor
